Related Experiment Video

Updated: Jun 24, 2026

Isolation and Flow Cytometric Analysis of Glioma-infiltrating Peripheral Blood Mononuclear Cells
12:52

Isolation and Flow Cytometric Analysis of Glioma-infiltrating Peripheral Blood Mononuclear Cells

Published on: November 28, 2015

Upregulation of LRIG1 suppresses malignant glioma cell growth by attenuating EGFR activity

Fei Ye1, Qinglei Gao, Tongjiang Xu

  • 1Department of Neurosurgery, Tongji Hospital, Tongji Medical College, Huazhong University of Science & Technology, 1095 Jie-Fang Avenue, Wuhan, Hubei, 430030, People's Republic of China. yeyuanbei@hotmail.com

Journal of Neuro-Oncology
|March 21, 2009
PubMed

Insights

LRIG1, a negative regulator of the epidermal growth factor receptor (EGFR), is downregulated in gliomas. Restoring LRIG1 inhibits glioma cell growth and promotes apoptosis, offering a potential new therapeutic target for malignant gliomas.

Area of Science:

  • Oncology
  • Molecular Biology
  • Cancer Research

Background:

  • Activated epidermal growth factor receptor (EGFR) is a key target in solid tumors, especially malignant gliomas.
  • LRIG1, a transmembrane glycoprotein, negatively regulates EGFR family receptor tyrosine kinases, acting as a tumor suppressor.
  • EGFR/LRIG1 ratio is significantly elevated in astrocytomas compared to non-neoplastic tissue.

Purpose of the Study:

  • To investigate the impact of LRIG1 on glioma cell biological features.
  • To elucidate the mechanisms of LRIG1-induced apoptosis.
  • To explore LRIG1 as a potential therapeutic target for malignant gliomas.

Main Methods:

  • Analysis of LRIG1 and EGFR expression in astrocytomas.
  • In vitro studies involving upregulation of LRIG1 in glioma cell lines and primary cells.
  • Assessment of downstream signaling pathways (MAPK, AKT) and caspase-8 activity.

Main Results:

  • LRIG1 expression is decreased, while EGFR expression is increased in most astrocytomas.
  • Upregulation of LRIG1 reduces cell surface EGFR, inhibits cell growth, induces apoptosis, and reverses invasion.
  • LRIG1 inhibits downstream MAPK and AKT signaling pathways, and increases caspase-8 release.

Conclusions:

  • LRIG1 functions as a negative feedback attenuator of EGFR in gliomas.
  • LRIG1 influences glioma cell fate and behavior by inhibiting key signaling pathways.
  • LRIG1 represents a promising novel therapeutic target for malignant gliomas.

Related Concept Videos

Mitogens and the Cell Cycle02:38

Mitogens and the Cell Cycle

Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
Receptor Downregulation in MVBs01:15

Receptor Downregulation in MVBs

Multivesicular bodies (MVBs) are mature endosomes that sort ubiquitinated proteins and then fuse with lysosomes to degrade the sorted proteins. Epidermal growth factor (EGF) and its receptor (EGFR) form a complex that can be internalized through endocytosis, sorted into an MVB, and later degraded.
The EGFR can initiate signaling pathways that  lead to cell proliferation, migration, and differentiation. Overexpression of EGFR  stimulates cells to proliferate. Excessive  EGFR activation may...
Abnormal Proliferation02:23

Abnormal Proliferation

Under normal conditions, most adult cells remain in a non-proliferative state unless stimulated by internal or external factors to replace lost cells. Abnormal cell proliferation is a condition in which the cell's growth exceeds and is uncoordinated with normal cells. In such situations, cell division persists in the same excessive manner even after cessation of the stimuli, leading to persistent tumors. The tumor arises from the damaged cells that replicate to pass the damage to the daughter...
PI3K/mTOR/AKT Signaling Pathway01:22

PI3K/mTOR/AKT Signaling Pathway

The mammalian target of rapamycin  (mTOR) is a serine/threonine kinase that regulates growth, proliferation, and cell survival in response to hormones, growth factors, or nutrient availability. This kinase exists in two structurally and functionally distinct forms: mTOR complex 1  (mTORC1) and mTOR complex 2  (mTORC2). The first form (mTORC1) is composed of a rapamycin-sensitive Raptor and proline-rich Akt substrate, PRAS40. In contrast,  mTORC2 consists of a rapamycin-insensitive companion...
The Retinoblastoma Gene01:20

The Retinoblastoma Gene

Tumor suppressor genes are normal genes that can slow down cell division, repair DNA mistakes, or program the cells for apoptosis in case of irreparable damage. Hence, they play an essential role in preventing the proliferation of damaged cells.
The first-ever tumor suppressor gene called Rb was identified in retinoblastoma - a rare eye tumor in children. In inherited forms of the disease, a child inherits one defective copy of the Rb gene, which predisposes them to retinoblastoma. However,...